# Sanofi: Phase 1 study in Healthy Volunteer (14 participants)

**Score:** 40/100

| Field | Value |
|---|---|
| Sponsor | Sanofi |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | An Open-label DDI Study to Investigate the Effect of Rilzabrutinib on P-gp, BCRP, OATP1B1 and OATP1B3 Inhibition |
| NCT ID | NCT07855250 |
| Phase | Phase 1 |
| Status | active not recruiting |
| Conditions | Healthy Volunteer |
| Intervention types | drug |
| Target enrollment | 14 |
| Site countries | Canada |
| Posted | 2026-10-02 |
| Planned start | 2026-10-01 |
| Event | Newly registered study |
| Event date | 2026-10-02 |

## Why this score
- Industry sponsor (buys outsourced services).

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07855250). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.